title: Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas.
abstract: BACKGROUND
  Scientific literature on infectious complications of chemotherapy in lymphomas is often based on retrospective studies or clinical trials performed with selected patients. This population may not be representative of the routine clinical practice. We aimed to analyse the incidence and type of infections associated to standard chemotherapy in clinically aggressive mature B and T cell lymphomas (AMBTL) and to detect baseline variables predictive of the risk of infection in a cohort of unselected patients.
  
  
  METHODS
  A prospective observational study of all the patients treated with first line chemotherapy for AMBTL in our Lymphoma Unit, in the setting of a community based teaching hospital, was performed. The statistical methods were univariate and multivariate analyses.
  
  
  RESULTS
  183 infectious episodes were registered in 97 (49%) of the 198 patients. Seventy-nine of them (43%) were associated to febrile neutropenia (27% of the patients). Microbiological documentation was obtained in 46% and only clinical documentation in 15%; 39% were classified as fever of unknown origin. Gram negative bacilli were the predominant aetiology. There were several variables related to risk of infection, but in multivariate analysis only a poor initial performance status was predictive of the risk of febrile neutropenia and infection during the first line chemotherapy.
  
  
  CONCLUSIONS
  In our cohort of AMBTL patients treated with first line chemotherapy, more than half of the relevant infections occurred without febrile neutropenia. A poor performance status was the only independent variable associated with the risk of febrile neutropenia or infection in the course of first line chemotherapy.
authors.affiliation: Department of Internal Medicine, Hospital de Cruces, Osakidetza, Vizcaya, Spain. juanjosealonso@telefonica.net
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Alonso
authors.forename: Araceli
authors.initials: A
authors.lastname: Cánovas
authors.forename: José Guillermo
authors.initials: JG
authors.lastname: Barreiro
authors.forename: Ciriaco
authors.initials: C
authors.lastname: Aguirre
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007239:Infections / Q000453:epidemiology* / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000453:epidemiology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology / Q000276:immunology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents